Search
VolitionRX Ltd
VNRXAdd to Watchlist
0.263USD
-0.002-0.75%
Close 09-22 16:00（ET）
3.05MMarket Cap
LossP/E TTM
Pre-market 05:17 (ET)0.262USD-0.001-0.38%
Pre-market 05:17 (ET)VolitionRX Ltd (VNRX) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to VolitionRX Ltd in the past month.
Buy
0 Strong Buy
4 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
13.622USD+5139.23%
VNRX Analyst Recommendation Trends
In the current month, VNRX has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VNRX average Analyst price target in the last month is 13.622.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
4
4
4
3
3
4
4
4
1
1
1
1
2
1
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
4
5
5
5
6
VNRX Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
11
14
3
0
0
28
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, VNRX EPS is projected to reach -0.428 in FY2026Q3, following reported EPS of -0.800 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.83
-0.72
-0.57
-0.43
-0.36
Actual
-1.04
-0.97
-0.80
--
--
Surprise
-24.38%
-34.49%
-39.41%
--
--
FAQs
What is VolitionRX Ltd's expected revenue for the next quarter?
VolitionRX Ltd's expected revenue is 706.50K.
What is VolitionRX Ltd's price target?
Analysts forecast that VolitionRX Ltd's price target is USD 13.62, with the highest forecast at USD 24.00 and the lowest forecast at USD 2.00.
How have VolitionRX LtdVNRX's recent earnings per share performed?
The market expectation was USD -0.80, while VolitionRX LtdVNRX's earnings per share (EPS) for the previous quarter was USD -0.97. EPS for the next quarter is expected at USD -0.43.
What is the analyst rating for VolitionRX Ltd?
Based on the ratings of VolitionRX Ltd's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.